169 related articles for article (PubMed ID: 30394165)
1. Venous thromboembolism prevention through the use of novel Factor Xa inhibitors.
Al-Hillan A; Bajwa RS; Cheema A; Ezeume A; Gor S; Mahida H; Kountz DS
Postgrad Med; 2019 Mar; 131(2):89-95. PubMed ID: 30394165
[TBL] [Abstract][Full Text] [Related]
2. Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.
Escolar G; Díaz-Ricart M; Arellano-Rodrigo E
Drugs Today (Barc); 2017 Aug; 53(8):423-434. PubMed ID: 29119147
[TBL] [Abstract][Full Text] [Related]
3. Betrixaban: Safely Reducing Venous Thromboembolic Events with Extended Prophylaxis.
Dobesh PP; Trevarrow BJ
Am J Med; 2019 Mar; 132(3):307-311. PubMed ID: 30201249
[TBL] [Abstract][Full Text] [Related]
4. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.
Nafee T; Gibson CM; Yee MK; Alkhalfan F; Chi G; Travis R; Mir M; Kalayci A; Jafarizade M; Ganti A; Kazmi SH; Ghaffarpasand E; Pitliya A; Datta S; Sharfaei S; Alihashemi M; Elsaiey A; Qamar I; Jahansouz M; Talib U; Kahe F; Habibi S; Abdelwahed M; Tariq F; Kaur M; Younes A; Walia SS; Singh A; Dildar SM; Afzal MK; Kerneis M
Expert Rev Cardiovasc Ther; 2018 Nov; 16(11):845-855. PubMed ID: 30296387
[TBL] [Abstract][Full Text] [Related]
5. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
Lu X; Lin J
BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
[TBL] [Abstract][Full Text] [Related]
7. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
8. Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis.
Neumann I; Rada G; Claro JC; Carrasco-Labra A; Thorlund K; Akl EA; Bates SM; Guyatt GH
Ann Intern Med; 2012 May; 156(10):710-9. PubMed ID: 22412038
[TBL] [Abstract][Full Text] [Related]
9. New paradigms in venous thromboprophylaxis of medically ill patients.
Spyropoulos AC; Raskob GE
Thromb Haemost; 2017 Aug; 117(9):1662-1670. PubMed ID: 28640324
[TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
Gibson CM; Halaby R; Korjian S; Daaboul Y; Arbetter DF; Yee MK; Goldhaber SZ; Hull R; Hernandez AF; Lu SP; Bandman O; Leeds JM; Gold A; Harrington RA; Cohen AT;
Am Heart J; 2017 Mar; 185():93-100. PubMed ID: 28267480
[TBL] [Abstract][Full Text] [Related]
11. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients.
Cave B; Hough A; Dobesh PP
Pharmacotherapy; 2018 Jun; 38(6):597-609. PubMed ID: 29543384
[TBL] [Abstract][Full Text] [Related]
12. Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.
Miller KM; Brenner MJ
Drugs; 2019 Feb; 79(3):291-302. PubMed ID: 30719631
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism prophylaxis after hospital discharge: transition to preventive care.
Kaatz S; Spyropoulos AC
Hosp Pract (1995); 2011 Aug; 39(3):7-15. PubMed ID: 21881387
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
[TBL] [Abstract][Full Text] [Related]
15. A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor.
Gomez D; Razmjou H; Donovan A; Bansal VB; Gollish JD; Murnaghan JJ
J Arthroplasty; 2017 Mar; 32(3):958-964. PubMed ID: 27843040
[TBL] [Abstract][Full Text] [Related]
16. The benefit of betrixaban for the extended thromboprophylaxis in acutely ill medical patients.
Scarpa D; Denas G; Babuin L; Pengo V
Expert Opin Pharmacother; 2019 Feb; 20(3):261-268. PubMed ID: 30615495
[TBL] [Abstract][Full Text] [Related]
17. Overview of betrixaban and its role in clinical practice.
Lekura J; Kalus JS
Am J Health Syst Pharm; 2018 Aug; 75(15):1095-1102. PubMed ID: 29941506
[TBL] [Abstract][Full Text] [Related]
18. Best practices for implementing venous thromboembolism prophylaxis across the continuum of care.
Dobesh PP; Ahuja T; Davis GA; Fatodu H; Francis WH; Hull FP; Johnson GL; Lenchus JD; Lenoir JG; McPherson C; Nemeth J; Riello RJ
Am J Manag Care; 2018 Nov; 24(22 Suppl):S483-S488. PubMed ID: 30452200
[No Abstract] [Full Text] [Related]
19. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
[TBL] [Abstract][Full Text] [Related]
20. Betrixaban: A Novel Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients.
Lee K; Cham S; Lam S
Cardiol Rev; 2018; 26(6):331-338. PubMed ID: 30067518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]